Date: 2016-06-29
Type of information: Collaboration agreement
Compound: high-resolution X-ray structures of G protein-coupled receptors (GPCRs)
Company: Heptares Therapeutics (UK), a wholly-owned subsidiary of Sosei Group (Japan) leadXpro (Switzerland)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On June 29, 2016, Heptares Therapeutics and leadXpro, a new spin off from the Paul Scherrer Institute (PSI), announced a collaboration to employ powerful new approaches for the determination of high-resolution X-ray structures of G protein-coupled receptors (GPCRs) to discover new drug lead compounds. leadXpro has deep expertise in biophysical and structure-based methods including serial crystallography and cryo-electron microscopy (cryo-EM), and applies these new techniques to the discovery and optimisation of innovative lead compounds targeting membrane proteins, such as GPCRs, ion channels and transporters. In the collaboration, Heptares will use its proprietary platform to generate conformationally stabilised GPCRs (StaR® proteins), which facilitate the formation of protein crystals. The teams will evaluate novel analytical methods for crystals that fail traditional X-ray crystallography techniques, using leadXpro’s expertise in high-powered X-ray technology at Swiss Light Source and free-electron laser technology at SwissFEL.
Financial terms:
Latest news:
